NCT06103279View on ClinicalTrials.gov

Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

August 31, 2024

Conditions
Cancer
Interventions
DRUG

Empagliflozin 10 MG

1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06103279 - Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin | Biotech Hunter | Biotech Hunter